The company, which supports governments and health authorities around the world to respond to the emergence of the new A (H1N1) influenza strain, is a manufacturer of both a traditional vaccine antigen as well as an adjuvant system.
The traditional vaccine antigen will be made from the newly isolated A (H1N1) influenza strain, while the adjuvant system can be added to the antigen at time of administration.
At present, GSK is working with the US Food and Drug Administration (FDA) and other government authorities in connection with its adjuvant and A (H1N1) candidate vaccine development.
As per company’s statement, it expects to fill the US adjuvant order within the next few months. The first dose of the vaccine antigen are expected to be available four to six months after the company gets the H1N1 seed strain, subject to regulatory approval.